Medical Advocates NNRTIs

Medical Advocates
NNRTIs

Main Page

New and Noteworthy Pediatric Data
General Reports Adolescent/Adult Data
Pharmacokinetics
Diagnostics/Monitoring
Viral Dynamics
Hypersusceptibility
Adherence
Resistance Data
Adverse Events
Drug/Drug Interactions
Efficacy
Virological Failure

Drugs Main Page HIV Main Page Main New/Newsworthy Home Page

Last Update: January 05, 2017
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

New and Noteworthy

January 2017

The choice between a ritonavir-boosted protease inhibitor- and a non-nucleoside reverse transcriptase inhibitor-based regimen for initiation of antiretroviral treatment - results from an observational study in Germany.
Mahlich J, Groß M, Kuhlmann A, et al J Pharm Policy Pract. 2016 Dec 30;9:39.

General Reports

Journal Papers, Abstracts, and Commentaries

The choice between a ritonavir-boosted protease inhibitor- and a non-nucleoside reverse transcriptase inhibitor-based regimen for initiation of antiretroviral treatment - results from an observational study in Germany.
Mahlich J, Groß M, Kuhlmann A, et al
J Pharm Policy Pract. 2016 Dec 30;9:39.
Abstract

FULL-TEXT ARTICLE
Long-term effectiveness of initiating non-nucleoside reverse transcriptase inhibitor- versus ritonavir-boosted protease inhibitor-based antiretroviral therapy: implications for first-line therapy choice in resource-limited settings.
Lima VD, Hull M, McVea D, et al
J Int AIDS Soc. 2016 Aug 5;19(1):20978.
Paper

Sociodemographic and clinical factors associated with the preference between NNRTIs and PIs for the initial treatment of HIV infection: Perfil-es study.
Viciana P, Ocampo A, Hevia H, et al
AIDS Care. 2016 May 3:1-6.
Abstract

Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors.
Famiglini V, Silvestri R.
Molecules. 2016 Feb 16;21(2). pii: E221. Review.
Abstract

Novel indole based NNRTIs with improved potency against wild type and resistant HIV.
Müller R, Mulani I, Basson AE, et al
Bioorg Med Chem Lett. 2014 Aug 13
Abstract

Review of the impact of NNRTI-based HIV treatment regimens on patient-reported disease burden.
Simpson KN, Hanson KA, Harding G, et al
AIDS Care. 2014 Apr;26(4):466-75.
Abstract

Clinical and analytical relevance of NNRTIs minority mutations on viral failure in HIV-1 infected patients.
Mohamed S, Ravet S, Camus C, et al
J Med Virol. 2014 Mar;86(3):394-403.
Abstract

Lack of Effect of Doxycycline on Trough Concentrations of Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients.
Abgrall S, Le Bel J, Lele N, et al
HIV Clin Trials. 2013 Nov-Dec;14(6):313-8
Abstract

Design of novel leads: ligand based computational modeling studies on non-nucleoside reverse transcriptase inhibitors (NNRTIs) of HIV-1
Jain Pancholi N, Gupta S, Sapre N, Sapre NS.
Mol Biosyst. 2013 Dec 2.
Abstract

Clinical Relevance of the Interaction when Switching Non-Nucleoside Reverse Transcriptase Inhibitors in Patients Infected with HIV.
Dailly E, Allavena C, Deslandes G, et al
Curr Clin Pharmacol. 2013 Nov 11..
Abstract

Review of the impact of NNRTI-based HIV treatment regimens on patient-reported disease burden.
Simpson KN, Hanson KA, Harding G, et alA
IDS Care. 2013 Oct 10.
Abstract

Patient reported outcome instruments used in clinical trials of HIV-infected adults on NNRTI-based therapy: a 10-year review.
Simpson KN, Hanson KA, Harding G, et al
Health Qual Life Outcomes. 2013 Oct 3;11(1):164..
Abstract

Nucleoside Reverse Transcriptase Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors in the Treatment of HIV Infections (AIDS).
De Clercq E.
Adv Pharmacol. 2013;67:317-58.
Abstract

Evaluation of residual viremia and quantitation of soluble CD14 in a large cohort of HIV-infected adults on a long-term non-nucleoside reverse transcriptase inhibitor-based regimen.
Allavena C, Rodallec A, Sécher S, et al
J Med Virol. 2013 Jul 16. .
Abstract

Rational Design of Potent Non-Nucleoside Inhibitors of HIV Reverse Transcriptase.
Peat AJ, Chong PY, Garrido DM, et al
J Med Chem. 2012 Nov 8.
Abstract

Structure-Activity Relationship Studies on Clinically Relevant HIV-1 NNRTIs.
Rawal RK, Murugesan V, Katti SB.
Curr Med Chem. 2012 Sep 10
Abstract

In search of a treatment for HIV - current therapies and the role of non-nucleoside reverse transcriptase inhibitors (NNRTIs).
Reynolds C, de Koning CB, Pelly SC, et al
Chem Soc Rev. 2012 May 22.
Abstract

The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia in HIV-infected patients: A case control study.
Cotte L, Bénet T, Billioud C, Miailhes P, et a
J Hepatol. 2010 Sep 19.
Abstract

Looking for an active conformation of the future HIV type-1 non-nucleoside reverse transcriptase inhibitors.
La Regina G, Coluccia A, Silvestri R.
Antivir Chem Chemother. 2010 Aug 11;20(6):213-
Abstract

Pharmacokinetics Data

Journal Papers, Abstracts, and Commentaries

Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability.
Usach I, Melis V, Peris JE
J Int AIDS Soc. 2013 Sep 4;16(1):1-14.
Abstract

Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside
resistance phenotype
Van Laethem K, Witvrouw M, Pannecouque C, et al.
AIDS 2001 Mar 30;15(5):553-61
Abstract

Diagnostics/Monitoring

Journal Papers, Abstracts, and Commentaries

An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma.
Weller DR, Brundage RC, Balfour HH Jr, Vezina HE. et al
J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Oct 31;
Abstract

Drug/Drug Interactions

Database of ARV Drug Interactions

Predictors of Clinically Significant Drug-Drug Interactions Among Patients Treated with Nonnucleoside Reverse Transcriptase Inhibitor-, Protease Inhibitor-, and Raltegravir-Based Antiretroviral Regimens (March).
Patel N, Abdelsayed S, Veve M, Miller CD
Ann Pharmacother. 2011 Mar 8.
Abstract

Efficacy Data

Journal Papers, Abstracts, and Commentaries

Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor-Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1: A Randomized, Controlled Equivalence Trial.
Lennox JL, Landovitz RJ, Ribaudo HJ, et al
Ann Intern Med. 2014 Oct 7;161(7):461-71.
Abstract

Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.
Gay CL, Mayo AJ, Mfalila CK, et al
AIDS. 2011 Apr 24;25(7):941-949.
Abstract

Viral Dynamics Data

Journal Papers, Abstracts, and Commentaries

Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or
both in INITIO: open-label randomised trial.INITIO Trial
International Co-ordinating Committee; Yeni P, Cooper DA, Aboulker JP, et al
Lancet. 2006 Jul 22;368(9532):287-98
Abstract

Nonnucleoside Reverse Transcriptase Inhibitor Fold Change or Plasma Concentration as
a Predictor of Virological Response over 48 Weeks in Highly Treatment Experienced
HIV-Positive Individuals.
Winston A, Amin J, Hales G, et al
AIDS Res Hum Retroviruses. 2006 Apr;22(4):338-41.
Abstract

Time to Virological Failure of 3 Classes of Antiretrovirals after Initiation of Highly Active Antiretroviral Therapy: Results from the EuroSIDA Study Group.
Mocroft A, Ledergerber B, Viard JP, et al.
J Infect Dis. 2004 Dec 1;190(11):1947-1956.
Abstract

Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy.
Parienti JJ, Massari V, Descamps D, et al
Clin Infect Dis. 2004 May 1;38(9):1311-6.
Abstract

Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral
suppression.
Negredo E, Cruz L, Paredes R, et al.
Clin Infect Dis 2002 Feb 15;34(4):504-10
Abstract

Hypersusceptibility

Journal Papers, Abstracts, and Commentaries

Drug resistance. NNRTI hypersusceptibility.
Delgado J, Shulman N.
AIDS Read. 2005 Jan;15(1):28-30, 32-4. R
Abstract

The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility:
a prospective cohort analysis.
Haubrich RH, Kemper CA, Hellmann NS, et al
AIDS 2002 Oct 18;16(15):F33-40
Abstract

Adherence

Journal Papers, Abstracts, and Commentaries

Adherence and persistence with non-nucleoside reverse transcriptase inhibitor-based antiretroviral regimens.
Taneja C, Juday T, Gertzog L et al
Expert Opin Pharmacother. 2012 Sep 13
Abstract

Effect of Adherence to HAART on Virologic Outcome and on the Selection of Resistance-Conferring Mutations in NNRTI- or PI-Treated Patients.
Maggiolo F, Airoldi M, Kleinloog HD, et al
HIV Clin Trials. 2007 Sep-Oct;8(5):282-92
Abstract

Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic
outcomes.
Nachega JB, Hislop M, Dowdy DW, et al
Ann Intern Med. 2007 Apr 17;146(8):564-73
Abstract

Resistance

Journal Papers, Abstracts, and Commentaries

Response to Therapy in Antiretroviral Therapy-Naïve Patients with Isolated Nonnucleoside Reverse-Transcriptase Inhibitor-Associated Transmitted Drug Resistance.
Clutter DS, Fessel WJ, Rhee SY, et al
J Acquir Immune Defic Syndr. 2016 Feb 5.
Abstract

FULL-TEXT ARTICLE
Emergent HIV-1 Drug Resistance Mutations Were Not Present at Low-Frequency at Baseline in Non-Nucleoside Reverse Transcriptase Inhibitor-Treated Subjects in the STaR Study
Porter DP, Daeumer M, Thielen A, et al
Viruses. 2015 Dec 7;7(12):6360-70.
Paper

FULL-TEXT ARTICLE
Recent Transmission Clustering of HIV-1 C and CRF17_BF Strains Characterized by NNRTI-Related Mutations among Newly Diagnosed Men in Central Italy.
Fabeni L, Alteri C, Orchi N, et al
PLoS One. 2015 Aug 13;10(8):e0135325.
Paper

Different Effects of Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Cytotoxic T Lymphocyte Recognition between HIV-1 Subtype B and Subtype A/E Infections.
Kuse N, Rahman MA, Murakoshi H, et al
J Virol. 2015 Jul 15;89(14):7363-72
Abstract

Minority resistant HIV-1 variants and the response to first-line NNRTI therapy.
Nicot F, Sauné K, Raymond S, et al
J Clin Virol. 2015 Jan;62:20-4.
Abstract

Clinical and analytical relevance of NNRTIs minority mutations on viral failure in HIV-1 infected patients.
Mohamed S, Ravet S, Camus C,et al
J Med Virol. 2013 Nov 19.
Abstract

Roles of the K101E Substitution in HIV-1 Reverse Transcriptase in Resistance to Rilpivirine and other Non-Nucleoside Reverse Transcriptase Inhibitors.
Xu HT, Colby-Germinario SP, Huang W, et al
Antimicrob Agents Chemother. 2013 Sep 3
Abstract

Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes.
Anta L, Blanco JL, Llibre JM, García F,et al
J Antimicrob Chemother. 2013 Apr 29
Abstract

The prevalence and economic burden of 1st-generation NNRTI resistance.
Snedecor S, Khachatryan A, Nedrow K, et al
J Int AIDS Soc. 2012 Nov 11;15(6):18204
Abstract

Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations,
adherence, and the risk of virologic failure.
Li JZ, Paredes R, Ribaudo HJ, et al
AIDS. 2012 Jan 14;26(2):185-192
Abstract

The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI(*).
Cozzi-Lepri A, Paredes R, Phillips A, et al
HIV Med. 2011 Aug 17
Abstract

Low-Frequency HIV-1 Drug Resistance Mutations and Risk of NNRTI-Based Antiretroviral Treatment Failure: A Systematic Review and Pooled Analysis.
Li JZ, Paredes R, Ribaudo HJ, et al
JAMA. 2011 Apr 6;305(13):1327-35.
Abstract

Nonnucleoside Reverse Transcriptase Inhibitor Concentrations During Treatment Interruptions and the Emergence of Resistance: A Substudy of the ISS-PART Trial.
Pirillo M, Palmisano L, Pellegrini M, et al
AIDS Res Hum Retroviruses. 2010 May 10
Abstract

A Novel Molecular Mechanism of Dual Resistance to NRTIs and NNRTIs.
Nikolenko GN, Delviks-Frankenberry KA, Pathak VK.
J Virol. 2010 Mar 10.
Abstract

Nonnucleoside Reverse Transcriptase Inhibitor Resistance and the Role of the
Second-Generation Agents
Adams J, Patel N, Mankaryous N, Tadros M, Miller CD.
Ann Pharmacother. 2009 Dec 8.
Abstract

Minority Variants Associated with Transmitted and Acquired HIV-1 Nonnucleoside Reverse Transcriptase Inhibitor Resistance: Implications for the Use of Second-Generation
Nonnucleoside Reverse Transcriptase Inhibitors.
Varghese V, Shahriar R, Rhee SY, et al
J Acquir Immune Defic Syndr. 2009 Sep
Abstract

HIV-1 Resistance to First- and Second-Generation Non-nucleoside Reverse Transcriptase Inhibitors.
Ghosn J, Chaix ML, Delaugerre C.
AIDS Rev. 2009 Jul-Sep;11(3):165-73
Abstract

Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
Tambuyzer L, Azijn H, Rimsky LT, et al
Antivir Ther. 2009;14(1):103-9.
Abstract

The human immunodeficiency virus type 1 (HIV-1) nonnucleoside reverse transcriptase inhibitor resistance mutation I132M confers hypersensitivity to nucleoside analogs.
Ambrose Z, Herman BD, Sheen CW,
J Virol. 2009 Feb 4
Abstract

Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase.
Ren J, Stammers DK
Virus Res. 2008 Feb 28
Abstract

Early Archiving and Predominance of Nonnucleoside Reverse Transcriptase Inhibitor-Resistant HIV-1 among Recently Infected Infants Born in the United States.
Persaud D, Palumbo P, Ziemniak C, et al
J Infect Dis. 2007 May 15;195(10):1402-10
Abstract

Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy.
Palmer S, Boltz V, Maldarelli F,et al
AIDS. 2006 Mar 21;20(5):701-710. R
Abstract

Prevalence of complete resistance to at least two classes of antiretroviral drugs in treated HIV-1-infected patients: A French nationwide study.
Masquelier B, Costagliola D, Schmuck A,0.
J Med Virol. 2005 Aug;76(4):441-6.
Abstract

Nonnucleoside Reverse Transcriptase Inhibitor Phenotypic Hypersusceptibility Can Be Demonstrated in Different Assays.
Shulman NS, Delgado J, Bosch RJ, et al
Acquir Immune Defic Syndr. 2005 May 1;39(1):78-81
Abstract

The effect of number of mutations and of drug-class sparing on virological response to salvage genotype-guided antiretroviral therapy.
Ciancio BC, Trotta MP, Lorenzini P, et al
Antivir Ther. 2003 Dec;8(6):611-6.
Abstract

Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure.
Antinori A, Zaccarelli M, Cingolani A, et al.
AIDS Res Hum Retroviruses 2002 Aug 10;18(12):835-8
Abstract

Prevalence of nonnucleoside reverse transcriptase inhibitor(NNRTI) resistance-associated mutations and polymorphisms inNNRTI-naive HIV-infected patients.
Clevenbergh P, Cua E, Dam E, et al.
HIV Clin Trials 2002 Jan-Feb;3(1):36-44
Abstract

Adverse Events

Journal Papers, Abstracts, and Commentaries

NNRTI-based antiretroviral therapy may increase risk of radiation induced side effects in HIV-1-infected patients.
Ulrike K, Markus H, Thomas H, et al
Radiother Oncol. 2015 Jul 13.
Abstract

FULL-TEXT PDF ARTICLE
Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe.
Frentz D, Van de Vijver DA, Abecasis AB, et al
BMC Infect Dis. 2014 Jul 21;14(1):407
Paper

Costs of adverse events among patients with HIV infection treated with nonnucleoside reverse transcriptase inhibitors.
Simpson K, Chen SY, Wu A, et al
HIV Med. 2014 Mar 18.
Abstract

Liver injury in HIV-1-infected patients receiving non-nucleosides reverse transcriptase inhibitors-based antiretroviral therapy.
Li ZC, Li HJ, Dai LL, et al
Chin Med J (Engl). 2010 Dec;123(24):3587-90.
Abstract

Twenty Years of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Time to Reevaluate their Toxicity.
Blas-Garcia A, Esplugues JV, Apostolova N. et al
Curr Med Chem. 2011 Apr 26.
Abstract

Decrease of vitamin D concentration in patients with HIV infection on a Non Nucleoside Reverse Transcriptase Inhibitor containing regimen.
Conesa-Botella A, Florence E, Lynen L, et al
AIDS Res Ther. 2010 Nov 23;7(1)
Abstract

Discontinuation of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy due to nucleoside analogue reverse transcriptase inhibitor-related metabolic toxicity.
Haddow LJ, Wood CW, Ainsworth JG .
Int J STD AIDS. 2007 May;18(5):343-6.
Abstract

Lipodystrophies related to antiretroviral treatment of HIV infection
Capeau J, Caron M, Vigouroux C,et al
Med Sci (Paris). 2006 May;22(5):531-536.
Abstract

Virological Failure

Journal Papers, Abstracts, and Commentaries

Response to Antiretroviral Treatment After Failure of NNRTI plus NRTIs-Based Therapy.
Data from the ARCA Collaborative Group.
Seminari E, De Silvestri A, Meini G, et al
Curr HIV Res. 2012 May 10.
Abstract

Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure.
Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES,
AIDS. 2012 Jan 14;26(2):185-192
Abstract

Pediatric Data

Journal Papers, Abstracts, and Commentaries

Growth Recovery Among HIV-Infected Children Randomized to Lopinavir/Ritonavir or NNRTI-Based Antiretroviral Therapy.
Achan J, Kakuru A, Ikilezi G, et al
Pediatr Infect Dis J. 2016 Aug 30
Abstract

Role of Non-Nucleoside Reverse Transcriptase Inhibitors in Treating HIV-Infected Children.
Penazzato M, Giaquinto C.
Drugs. 2011 Nov 12;71(16):2131-49
Abstract

Pattern and Predictors of Immunologic Recovery in Human Immunodeficiency Virus-Infected Children Receiving Non-Nucleoside Reverse Transcriptase Inhibitor-Based Highly Active Antiretroviral Therapy.
Puthanakit T, Kerr SJ, Ananworanich J, et al
Pediatr Infect Dis J. 2009 Apr 28.
Abstract

Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children.
Cressey TR, Green H, Khoo S, et al
Clin Infect Dis. 2008 May 15;46(10):1601-8
Abstract

The role of non-nucleoside reverse transcriptase inhibitors in children with HIV-1 infection.
Maddocks S, Dwyer D.
Paediatr Drugs 2001;3(9):681-702
Abstract

Adolescent/Adult Data

Journal Papers, Abstracts, and Commentaries

Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy in Perinatally HIV-Infected, Treatment-Naïve Adolescents in Asia.
Boettiger DC, Sudjaritruk T, Nallusamy R, et al
J Adolesc Health. 2016 Jan 20.
Abstract

Effect of Non-Nucleoside Reverse Transcriptase Inhibitors on Cytokine, Chemokine, and Immunoglobulin Profiles in Serum and Genital Secretions of HIV-Infected Women.
Sachdeva RK, Wanchu A, Bagga R, et al
J Interferon Cytokine Res. 2010 Feb 28
Abstract

Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women.
Gandhi M, Benet LZ, Bacchetti P, et al
J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):482-91
Abstract

Restoration of human immunodeficiency virus-1-specific responses in patients changing from protease to non-nucleoside reverse transcriptaseinhibitor-based antiretroviral therapy.
Sullivan AK, Burton CT, Nelson MR
Scand J Immunol. 2003 Jun;57(6):600-7.
Abstract

Substitution of a nonnucleoside reverse transcriptase inhibitor for a protease inhibitor in the treatment of patients with undetectable plasma human immunodeficiency virus type 1 RNA.
Raffi F, Bonnet B, Ferre V, et al.
Clin Infect Dis 2000 Nov;31(5):1274-8
Abstract

Drugs Main Page HIV Main Page Main New/Newsworthy Home Page

Non-Nucleoside Reverse Transcriptase Inhibitors